Brief: Grand Pharmaceutical Says Novasync Approved By NMPA For Commercialization In China
12/12/2024 10:23
Dec 12 (Reuters) - Grand Pharmaceutical Group Ltd
0512.HK :
* GLOBAL INNOVATIVE INTRAVASCULAR DUAL-MODE IMAGING SYSTEM
NOVASYNC APPROVED BY NMPA FOR COMMERCIALIZATION IN CHINA
Further company coverage: 0512.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Grand Pharmaceutical
See all newsBrief: Grand Pharmaceutical Group Declares No Interim Dividend Has Been Paid
Grand Pharmaceutical H1 revenue rises on nuclear medicine demand
Grand Pharma rises most in over a year as drug gets US FDA fast track designation
GPN01530-2 Granted Fast Track Designation By FDA
Brief: Grand Pharmaceutical Group Enters Huadong Medicine Supply Agreement